Cationic Lipids Alter Tumor Microenvironment for Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies face challenges in effectively reducing the population of immune suppressive regulatory T-cells (Tregs) within tumors while increasing tumor lysing CD8+ T-cells, leading to suboptimal anti-tumor responses due to the immunosuppressive tumor microenvironment.
Innovation Solution
The use of cationic lipids to alter the tumor microenvironment by reducing Treg populations and facilitating antigen presentation to CD4+ and CD8+ T-cells, thereby enhancing anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer immunotherapies are used, then treatment is administered, but the population of immune suppressive regulatory T-cells (Tregs) is not effectively reduced and tumor lysing CD8+ T-cells are not sufficiently increased
Solution Approach 1:
The patent applies parameter changes by using cationic lipids to alter the chemical and physical properties of the tumor microenvironment. These lipids modify membrane properties, facilitate antigen presentation, and shift the balance between Treg and CD8+ T-cell populations, thereby improving anti-tumor response effectiveness while reducing Treg quantity.
Solution Approach 2:
Cationic lipids serve as intermediary substances that mediate between the administered therapy and the tumor microenvironment. They facilitate the interaction between antigens and T-cells, enhance antigen presentation to CD4+ and CD8+ T-cells, and indirectly reduce Treg suppressive activity, thus improving therapeutic effectiveness.
2Productivity
If the tumor microenvironment is left unchanged, then treatment simplicity is maintained, but CD8+ T-cell infiltration is insufficient for effective tumor lysis
Solution Approach 1:
The cationic lipids enable the treatment to partially serve itself by autonomously facilitating antigen presentation and enhancing T-cell infiltration without requiring complex external interventions. The lipids self-assemble, interact with cell membranes, and trigger the necessary immune responses, simplifying the overall treatment approach while improving CD8+ T-cell productivity.
3Reliability
If multiple therapies are combined to address immunosuppression, then comprehensive coverage is achieved, but treatment complexity and potential side effects increase
Solution Approach 1:
The cationic lipids exhibit multi-functionality, serving as both antigen presentation facilitators, T-cell activation enhancers, and Treg activity modulators. This universal approach allows a single agent to address multiple aspects of immunosuppression that would otherwise require multiple separate therapies, thereby broadening therapeutic spectrum while reducing treatment complexity.
Data Source
AI summary
Methods and compositions for altering the microenvironment of a tumor are provided. The methods comprise reducing the population of tumor-residing immune suppressive regulatory T-cells, increasing the population of tumor lysing T-cells (such as CD8+ T-cells) and improving the efficacy of cancer immunotherapy. The compositions comprise the use of cationic lipids optionally combined with autologous antigens, non-autologous antigens, or tumor-associated antigens.